Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pcDNA-DEST47-TOP2A (#RDB15801)

Gateway(R) expression vector of human TOP2A.

Clone info. Gateway(R) expression vector of human topoisomerase 2 alpha (TOP2A) fused with GFP at C-terminal, CMV promoter.
Vector backbone pcDNA-DEST47 (plasmid)
Size of vector backbone 7.8 kb
Selectable markers Amp^r (E. coli), Neo^r (mammalian cells).
Gene/insert name human TOP2A cDNA
Depositor|Developer Kondo, Yutaka |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
MTA, for use for for-profit purpose [Word]
Approval form by depositor [Word]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Katsushima, K et al. Nat. Commun. 7: 13616, 2016); (Deguchi, S et al. Oncogene. 36 (32) : 4629 - 4640, 2017). RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR.
Remarks ((Additional form)) Approval Form(FormD)
Please obtain written approval of the depositor.
Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
提供同意書 (MTA, 営利目的用)[Word]
寄託者による提供承諾書 [Word]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は提供承諾書を用いて、事前に寄託者の承諾を得る。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Katsushima, K et al. Nat. Commun. 7: 13616, 2016); (Deguchi, S et al. Oncogene. 36 (32) : 4629 - 4640, 2017)。利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。
備考 【追加提供依頼書】承諾書(FormD)
寄託者の書面による提供承諾が必要です。
Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15801 pcDNA-DEST47-TOP2A DNA solution

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pcDNA-DEST47-TOP2A was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15801).

Reference section:

Deguchi, S., Katsushima, K., Hatanaka, A., Shinjo, K., Ohka, F., Wakabayashi, T., Zong, H., Natsume, A., Kondo, Y., Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene 36 (32): 4629-4640 (2017). PMID 28368417. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15801_A8Bqp1-3.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV_Forward (Pr0016)
Region: CMV pro,attB1,insert 5'
Sequence file: RDB15801_A8Bqe.seq check
>D05196A8-6_A8Bq_CMV_Forward_E02_2018-03-19-14-24-28_14.ab1
    1 NNNNNNNNNN NNNCNTNGNN GCNNTGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA
   61 GCAGAGCTCT CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA
  121 CTCACTATAG GGAGACCCAA GCTGGCTAGT TAAGCTTGAT CAAACAAGTT TGTACAAAAA
  181 AGCAGGCTCC GCGGCCGCCC CCTTCACCAT GGAAGTGTCA CCATTGCAGC CTGTAAATGA
  241 AAATATGCAA GTCAACAAAA TAAAGAAAAA TGAAGATGCT AAGAAAAGAC TGTCTGTTGA
  301 AAGAATCTAT CAAAAGAAAA CACAATTGGA ACATATTTTG CTCCGCCCAG ACACCTACAT
  361 TGGTTCTGTG GAATTAGTGA CCCAGCAAAT GTGGGTTTAC GATGAAGATG TTGGCATTAA
  421 CTATAGGGAA GTCACTTTTG TTCCTGGTTT GTACAAAATC TTTGATGAGA TTCTAGTTAA
  481 TGCTGCGGAC AACAAACAAA GGGACCCAAA AATGTCTTGT ATTAGAGTCA CAATTGATCC
  541 GGAAAACAAT TTAATTAGTA TATGGAATAA TGGAAAAGGT ATTCCTGTTG TTGAACACAA
  601 AGTTGAAAAG ATGTATGTCC CAGCTCTCAT ATTTGGACAG CTCCTAACTT CTAGTAACTA
  661 TGATGATGAT GAAAAGAAAG TGACAGGTGG TCGAAATGGC TATGGAGCCA AATTGTGTAA
  721 CATATTCAGT ACCNAATTTA CTGTGGAAAC AGCCAGTAGA GAATACAAGA AAATGTTCNA
  781 ACAGACNTGG NTGGATAATA TGGGAAGANC TGGTGAGATG NAACTCNAGC CNNNCNNNGG
  841 NNAAGANTAT ACATGTATCA CCTTTCANCC NNNNTTGTCT AAGTTTNAAA TGNNAAGCNN
  901 NNNNNANGAT ATTGNNGCNC NNNNGGNCNN NNNANCATAT GANATTGCNN GNNTNNNNNN
961 ANNNNNNNNA NNNNNTTNNN NNNNNNN
//
Primer: GFP-N_R (Pr0466)
Region: Cycle 3 GFP,attB2,stop codon,insert 3'
Sequence file: RDB15801_A8Bqf.seq check
>D05196A8-6_A8Bq_GFP-N_R_F02_2018-03-19-14-24-28_17.ab1
    1 NNNNNNNNNN NNNNNNNNNN NGNNNNNNTC TTCTCCTTTG CTAGCCATTC TAGATCGAAC
   61 CACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT TAAAACAGAT CATCTTCATC
  121 TGACTCTTCC AGGTACTTTA TAGGTTTCTT TGCCCGTACA GATTTTGCCC GAGGAGCCAC
  181 AGCTGAGTCA AAGTCCATAT GGAAGTCATC ACTCTCCCCC TTGGATTTCT TGCTTGTGAC
  241 TGCTTTCGAA ACAATTTTCT CAAAATTAGA GTCAGAATCA TCAGAAGTGG ATGGCTTCCT
  301 TTTGCGGCGA TTCTTGGTTT TGGCAGGATC AGGCTTTTGA GAGACACCAG AATTCAAAGC
  361 TGGATCCCTT TTAGTTCCTT TTGGGGCAGC CCTTTTTTTG GCACCGGTAG TGGAGGTGGA
  421 AGACTGACTT TTTGCTGCTG TCTTCTTCAC TGTCACATTC TTTTTAGGAA CTGGGTTTGT
  481 AATTTCAGTT TCATCTGGGA AATGTGTAGC AGGAGGGCTT GAAGACAGTG GTACACTGCC
  541 CTTAACATCA TCAGCTTCAA GGTCTGACAC GACACTTTTC TGTGGTTTCA GTTCTTTGTT
  601 ACTAAGTTTT GGGGAAGTTT TGGTCTTAGG TGGACTAGCA TCTGATGGGA CAAAATCTTC
  661 ATCATCAGTT TTTTCATCAA AATCTGAGAA ATCTTCATCT GAATCCAAAT CCATTGTGAA
  721 TTTTGNTTTT GTTGCTGCTC TCCGTGGCTC TGTTTCTCGT GGANGGACAT CAAAATTACT
  781 TTCGTCACTG CTCCTATCTG ANTCTGAATC AGANCAGGGN NTTCTCTTCT TTCCTTTTTT
  841 TGATTGGCTT AAATGCCAAT GNAGTTTGTT TCTTTGNCTT TGTACCTGGT TCTCTTTTCT
  901 GNTTCTTTTC TAATCTTTGN TTTNNGNCTT CNANTTNCNC ACNANNNTNN TTGNNGGNNT
961 NNNNCANNAT TTTCNNNNNN NANNTTNNNT TNTNNNTTTN NNNTNNNNNN NNNN
//
Primer: BGH_rev2 (Pr0606)
Region: bGHpA,Cycle 3 GFP
Sequence file: RDB15801_A8Bqg.seq check
>D05196A8-6_A8Bq_BGH_rev2_G02_2018-03-19-14-24-28_20.ab1
    1 NNNNNNNNNN NNNNNNNNNG NNNNNNNNNN GGGCNNACNA CAGATGGCTG GCAACTAGAA
   61 GGCACAGTCG AGGCTGATCA GCGGGTTTAA TTCATTATTT GTAGAGCTCA TCCATGCCAT
  121 GTGTAATCCC AGCAGCAGTT ACAAACTCAA GAAGGACCAT GTGGTCACGC TTTTCGTTGG
  181 GATCTTTCGA AAGGGCAGAT TGTGTCGACA GGTAATGGTT GTCTGGTAAA AGGACAGGGC
  241 CATCGCCAAT TGGAGTATTT TGTTGATAAT GGTCTGCTAG TTGAACGGAT CCATCTTCAA
  301 TGTTGTGGCG AATTTTGAAG TTAGCTTTGA TTCCATTCTT TTGTTTGTCT GCCGTGATGT
  361 ATACATTGTG TGAGTTATAG TTGTACTCGA GTTTGTGTCC GAGAATGTTT CCATCTTCTT
  421 TAAAATCAAT ACCTTTTAAC TCGATACGAT TAACAAGGGT ATCACCTTCA AACTTGACTT
  481 CAGCACGCGT CTTGTAGTTC CCGTCATCTT TGAAAGATAT AGTGCGTTCC TGTACATAAC
  541 CTTCGGGCAT GGCACTCTTG AAAAAGTCAT GCCGTTTCAT ATGATCCGGA TAACGGGAAA
  601 AGCATTGAAC ACCATAAGAG AAAGTAGTGA CAAGTGTTGG CCATGGAACA GGTAGTTTTC
  661 CAGTAGTGCA AATAAATTTA AGGGTAAGCT TTCCGTATGT AGCATCACCT TCACCCTCTC
  721 CACTGACAGA AAATTTGTGC CCATTAACAT CACCATCTAA TTCAACAAGA ATTGGGACAA
  781 CTCCAGTGAA AAGTTCTTCT CCTTTGCTAN CCATTCTAGA TCGAACCACT TTGTACAAGA
  841 AAGCTGGGTC GGCGCGCCNA CCCTTTTAAA ACAGATCATC TTCATCTGAN TCTTNNANGT
  901 ACTTNATAGG TTTCTTTGCC CGNACAGATT TTGCCNNAGG ANCCNCANCN GANNNNAANN
961 NCATATNGNA ANNNATCNCN CTNCCCNNNT NNNNNTNNNT NNNNNNNNNN
//
Primer: SV40pro_F (Pr0110)
Region: NeoR
Sequence file: RDB15801_A8Bqh.seq check
>D05196A8-6_A8Bq_SV40pro_F_H02_2018-03-19-14-24-28_23.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNNNNNNNTG ANGNNGNTTT TTTGGAGGCC TAGGCTTTTG
   61 CAAAAAGNNN NNGGGNGCTT GTATATCNNT TTTCGGATCT GATCAAGAGA CAGGATGAGG
  121 ATCGTTTCGC ATGATTGAAC AAGATGGATT GCACGCAGGT TCTCCGGCCG CTTGGGTGGA
  181 GAGGCTATTC GGCTATGACT GGGCACAACA GACAATCGGC TGCTCTGATG CCGCCGTGTT
  241 CCGGCTGTCA GCGCAGGGGC GCCCGGTTCT TTTTGTCAAG ACCGACCTGT CCGGTGCCCT
  301 GAATGAACTG CAGGACGAGG CAGCGCGGCT ATCGTGGCTG GCCACGACGG GCGTTCCTTG
  361 CGCAGCTGTG CTCGACGTTG TCACTGAAGC GGGAAGGGAC TGGCTGCTAT TGGGCGAAGT
  421 GCCGGGGCAG GATCTCCTGT CATCTCACCT TGCTCCTGCC GAGAAAGTAT CCATCATGGC
  481 TGATGCAATG CGGCGGCTGC ATACGCTTGA TCCGGCTACC TGCCCATTCG ACCACCAAGC
  541 GAAACATCGC ATCGAGCGAG CACGTACTCG GATGGAAGCC GGTCTTGTCG ATCAGGATGA
  601 TCTGGACGAA GAGCATCAGG GGCTCGCGCC AGCCGAACTG TTCGCCAGGC TCAAGGCGCG
  661 CATGCCCGAC GGCGAGGATC TCGTCGTGAC CCATGGCGAT GCCTGCTTGC CGAATATCAT
  721 GGTGGAAAAT GGCCGCTTTT CTGGATTCAT CGACTGTGGC CGGCTGGGTG TGGCGGACCG
  781 CTATCAGGAC ATAGCGTTGG CTACCCGTGA TATTGCTGAA GAGCTTGNCG GCNAATGGGC
  841 TGANCGCTTC CTCGTGCTTT ACGGNATCGC CGCNCCNNAN TCGCANCGCN TCGCCNNCTA
  901 TCGCCNTCTT GACNANTTCT TCTGANCGGG ANNNNNGGGN NNCNCGAAAT GANNGANCNN
961 NGCNNNNNCN NNNCNNNNCN NNNNNNANNN TNNNNNNNNN N
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Deguchi, S., Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis. Oncogene 36 (32): 4629-4640 (2017). PMID 28368417. [link to RRC of NBRP]